RARE - Company ID 0001515673
The table below shows Ultragenyx Pharmaceutical Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $136.00M | $159.93M | $166.50M | $139.00M | $139.49M | $147.03M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $187.00M | $216.21M | $164.74M | $166.00M | $170.11M | $161.50M |
Ultragenyx Pharmaceutical Inc. reported annual revenue of $673.00M for fiscal year 2025. That is up 20.2% from $560.00M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $133.00K (FY 2016) to $673.00M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $88.00M |
| $86.62M |
| $86.65M |
| $87.00M |
| $80.35M |
| $80.60M |
| Operating income | -$169.00M | -$170.89M | -$107.89M | -$143.00M | -$131.99M | -$116.36M |
| Income tax | $1.00M | $873.00K | $947.00K | $1.00M | $303.00K | $858.00K |
| Net income | -$185.00M | -$180.41M | -$114.95M | -$151.00M | -$133.52M | -$131.60M |
| EPS (diluted) | -$1.84 | -$1.81 | -$1.17 | -$1.57 | -$1.40 | -$1.52 |